Jackson Hole Capital Partners LLC Sells 6,686 Shares of Zoetis Inc. $ZTS

Jackson Hole Capital Partners LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 33.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,170 shares of the company’s stock after selling 6,686 shares during the quarter. Jackson Hole Capital Partners LLC’s holdings in Zoetis were worth $1,657,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the stock. Bogart Wealth LLC lifted its holdings in shares of Zoetis by 48.1% in the fourth quarter. Bogart Wealth LLC now owns 351 shares of the company’s stock worth $44,000 after buying an additional 114 shares in the last quarter. Sage Rhino Capital LLC lifted its stake in Zoetis by 13.4% in the 4th quarter. Sage Rhino Capital LLC now owns 8,928 shares of the company’s stock worth $1,123,000 after purchasing an additional 1,054 shares in the last quarter. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Zoetis during the fourth quarter valued at about $50,000. Vest Financial LLC grew its position in shares of Zoetis by 13.0% during the fourth quarter. Vest Financial LLC now owns 2,116 shares of the company’s stock valued at $266,000 after purchasing an additional 243 shares in the last quarter. Finally, Cadence Bank bought a new stake in shares of Zoetis in the fourth quarter worth about $3,618,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

NYSE:ZTS opened at $114.51 on Thursday. The firm has a market capitalization of $48.17 billion, a price-to-earnings ratio of 19.03, a PEG ratio of 1.80 and a beta of 0.98. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The business has a 50 day simple moving average of $120.17 and a 200-day simple moving average of $124.86. Zoetis Inc. has a 1 year low of $112.97 and a 1 year high of $172.23.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts forecast that Zoetis Inc. will post 7.02 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.9%. Zoetis’s dividend payout ratio is currently 35.22%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ZTS shares. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. BTIG Research reissued a “buy” rating and issued a $160.00 target price on shares of Zoetis in a report on Thursday, February 26th. Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Citigroup initiated coverage on shares of Zoetis in a research note on Wednesday, April 15th. They set a “buy” rating and a $145.00 price target on the stock. Finally, Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Zoetis has an average rating of “Hold” and a consensus target price of $151.75.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.